Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Toi, Masakazu, Inoue, Kenichi, Masuda, Norikazu, Iwata, Hiroji, Sohn, Joohyuk, Hae Park, In, Im, Seock‐Ah, Chen, Shin‐Cheh, Enatsu, Sotaro, Turner, P. Kellie, André, Valérie A. M., Hardebeck, Molly C., Sakaguchi, Sachi, Goetz, Matthew P., Sledge, George W.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177785/
https://ncbi.nlm.nih.gov/pubmed/33686753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14877
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars